Monitor for COVID-19 vaccine resistance evolution during clinical trials

Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, David A., Read, Andrew F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676675/
https://www.ncbi.nlm.nih.gov/pubmed/33166303
http://dx.doi.org/10.1371/journal.pbio.3001000
Descripción
Sumario:Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.

Ejemplares similares